L-天冬氨酰胺酸乙酯 | 24184-58-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-天冬氨酰胺酸乙酯
• 中文别名: 丙酰胺,N-(6-氨基-1,2,3,4-四氢-1,3-二甲基-2,4-二羰基-5-嘧啶基)-2,2,3,3,3-五氟-
• 英文名称: L-asparagin-ethylester
• 英文别名: asparagine ethyl ester；Ethyl L-asparaginate；ethyl (2S)-2,4-diamino-4-oxobutanoate
• CAS: 24184-58-5
• 化学式: C₆H₁₂N₂O₃
• 分子量: 160.173
• InChiKey: ZTCCUHKCQDSJPK-BYPYZUCNSA-N

物化性质

• 沸点：
  335.5±32.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  95.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  L-天冬氨酰胺酸乙酯 、 在 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-2-((R)-2-Benzyloxycarbonylamino-3-tritylsulfanyl-propionylamino)-succinamic acid ethyl ester
  参考文献：
  名称：

  含硫的多肽。十二。研究硫代硫氰酸盐方法作为胱氨酸肽途径的范围和局限性。

  摘要：

  DOI：

  10.1021/jo00829a056

文献信息

• TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO
  申请人：GOURDEAU Henriette

  公开号：US20090062255A1

  公开（公告）日：2009-03-05

  The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said receptor, such as a peripheral benzodiazepine receptor, is produced in a greater amount by said cancer cell than by a normal cell; and to inhibit the activity of at least one protein member of the MAPK pathway. The invention further relates to dibenzodiazepinone analogues and derivatives thereof.

  该发明涉及一种评估候选分子化疗潜力的方法。在评估候选分子时，将测试候选分子抑制癌细胞体外生长的能力；结合由癌细胞产生的细胞受体，其中所述受体，如外周苯二氮卓受体，由所述癌细胞产生的数量比正常细胞多；并抑制MAPK通路中至少一个蛋白质成员的活性。该发明还涉及二苯二氮卓酮类似物及其衍生物。
• COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS
  申请人：Innovaprotean, S.L.

  公开号：EP1679299A1

  公开（公告）日：2006-07-12

  SUMMARY The present invention provides new amyloidogenesis inhibiting compounds of formula (I): in which R1 is a -NRaRb group, where Ra and Rb, independently, are a hydrogen atom or a C1-C6 alkyl group; -ORc group, where Rc is a hydrogen atom or a C1-C6 alkyl group; a glycosyl; a C1-C6 polyhydroxyalkyl; or a -NH-CH(Rd)-COORe group, where Rd is a side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and Re is a hydrogen atom or a C1-C6 alkyl group; and R2 is a hydrogen atom, a C1-C6 alkyl group, a glycosyl; a C1-C6 polyhydroxyalkyl; -C(=O)-Rf group, where Rf is a C1-C6 alkyl group; or a -CH2-COO-Rg group, where Rg is a hydrogen atom or a C1-C6 alkyl group; and pharmaceutically acceptable salts thereof, which are useful in the treatment of neurodegenerative diseases, among others.

  本发明提供了新的抑制淀粉样生成的化合物，其化学式为（I）：其中R1是一个-NRaRb基团，其中Ra和Rb独立地是氢原子或C1-C6烷基基团；-ORc基团，其中Rc是氢原子或C1-C6烷基基团；一种糖基；一种C1-C6多羟基烷基；或者一个-NH-CH（Rd）-COORe基团，其中Rd是20种天然α-氨基酸之一的侧链，以其两种对映纯形式L或D之一存在，Re是氢原子或C1-C6烷基基团；和R2是氢原子，C1-C6烷基基团，糖基；C1-C6多羟基烷基；-C（=O）-Rf基团，其中Rf是C1-C6烷基基团；或者-CH2-COO-Rg基团，其中Rg是氢原子或C1-C6烷基基团；以及其药学上可接受的盐，这些化合物在治疗神经退行性疾病等方面是有用的。
• COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS
  申请人：Saraiva Mascarenhas Maria Joao

  公开号：US20070167378A1

  公开（公告）日：2007-07-19

  The present invention provides new amyloidogenesis inhibiting compounds of formula (I): in which R 1 is a —NR a R b group, where R a and R b , independently, are a hydrogen atom or a C 1 -C 6 alkyl group; —OR c group, where R c is a hydrogen atom or a C 1 -C 6 alkyl group; a glycosyl; a C 1 -C 6 polyhydroxyalkyl; or a —NH—CH(R d )—COOR e group, where R d is a side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and R e is a hydrogen atom or a C 1 -C 6 alkyl group; and R 2 is a hydrogen atom, a C 1 -C 6 alkyl group, a glycosyl; a C 1 -C 6 polyhydroxyalkyl; —C(═O)—R f group, where R f is a C 1 -C 6 alkyl group; or a —CH 2 —COO—R g group, where R g is a hydrogen atom or a C 1 -C 6 alkyl group; and pharmaceutically acceptable salts thereof, which are useful in the treatment of neurodegenerative diseases, among others.

  本发明提供了一种新的抑制淀粉样蛋白生成的化合物，其化学式为(I)：其中，R1是—NRaRb基团，其中Ra和Rb独立地是氢原子或C1-C6烷基基团；—ORc基团，其中Rc是氢原子或C1-C6烷基基团；糖基；C1-C6聚羟基烷基；或—NH—CH(Rd)—COORegroup基团，其中Rd是20种天然α-氨基酸之一的侧链，它们分别以其两个对映异构体纯形式L或D存在，而Re是氢原子或C1-C6烷基基团；而R2是氢原子，C1-C6烷基基团，糖基，C1-C6聚羟基烷基；—C(═O)—Rf基团，其中Rf是C1-C6烷基基团；或—CH2—COO—Rg基团，其中Rg是氢原子或C1-C6烷基基团；以及其药学上可接受的盐，这些化合物在神经退行性疾病的治疗中等方面有用。
• Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
  申请人：McAlpine B. James

  公开号：US20060079509A1

  公开（公告）日：2006-04-13

  The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.

  本发明涉及由式 I 表示的具有生物活性的二苯并二氮杂卓类似物、生产它们的方法、包含它们的药物组合物以及治疗肿瘤疾病的方法。
• Polycyclic aromatics and derivatives thereof and processes for their preparation
  申请人：McAlpine B. James

  公开号：US20060106028A1

  公开（公告）日：2006-05-18

  This invention relates to novel biologically active polycyclic aromatics produced by cultivation of Micromonospora echinospora ssp. challisensis NRRL 12255. The invention also relates to their pharmaceutically acceptable salts, prodrugs and derivatives, and to methods of obtaining them by post-biosynthesis chemical modification. The invention further relates to the use of the polycyclic aromatics and their derivatives in the preparation of medicaments for the treatment of neoplastic conditions and bacterial infections.

  本发明涉及新型生物活性多环芳烃，通过培养 小单胞菌 ssp. 菌株产生的新型生物活性多环芳烃。 NRRL 12255。本发明还涉及它们的药学上可接受的盐、原药和衍生物，以及通过生物合成后化学修饰获得它们的方法。本发明还涉及多环芳烃及其衍生物在制备治疗肿瘤和细菌感染的药物中的用途。